Allogeneic CAR-19 Regulatory T CellsTherapy（Masonic Cancer Center）

异基因CAR-19调节性T细胞疗法（Masonic Cancer Center）

Report date: 2024/07/20 20:00:10

Base Information

Drug NameAllogeneic CAR-19 Regulatory T CellsTherapy（Masonic Cancer Center）
Drug Alias Nameallogeneic CAR19 regulatory T cells（Masonic Cancer Center）CAR19-tTreg
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMasonic Cancer Center, University Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMasonic Cancer Center, University Of Minnesota
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphoid

Other Information

ATC CodeN/A
Related LinksN/A